Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Autor: Razavi, H. Robbins, S. Zeuzem, S. Negro, F. Buti, M. Duberg, A. Roudot-Thoraval, F. Craxi, A. Manns, M. Marinho, R.T. Hunyady, B. Colombo, M. Aleman, S. Antonov, K. Arkkila, P. Athanasakis, K. Blach, S. Blachier, M. Blasco, A.J. Calinas, F. Calleja, J.L. Christensen, P.B. Cramp, M.E. Croes, E. de Knegt, R.J. de Ledinghen, V. Delile, J.-M. Estes, C. Falconer, K. Färkkilä, M. Flisiak, R. Frankova, S. Gamkrelidze, I. García-Samaniego, J. Genov, J. Gerstoft, J. Gheorghe, L. Goldis, A. Gountas, I. Gregorčič, S. Gschwantler, M. Gunter, J. Halota, W. Harcouet, L. Hézode, C. Hoffmann, P. Horvath, G. Hrstic, I. Jarčuška, P. Jelev, D. Jeruma, A. Kåberg, M. Kieran, J. Kondili, L.A. Kotzev, I. Krarup, H. Kristian, P. Lagging, M. Laleman, W. Lázaro, P. Liakina, V. Lukšić, B. Maimets, M. Makara, M. Mateva, L. Maticic, M. Mennini, F.S. Mitova, R. Moreno, C. Mossong, J. Murphy, K. Nde, H. Nemecek, V. Nonkovic, D. Norris, S. Oltman, M. Øvrehus, A.L.H. Papatheodoridis, G. Pasini, K. Razavi-Shearer, D. Razavi-Shearer, K. Reesink, H.W. Reic, T. Rozentale, B. Ryder, S.D. Salupere, R. Sarmento-Castro, R. Sarrazin, C. Schmelzer, J.D. Schréter, I. Seguin-Devaux, C. Simojoki, K. Simonova, M. Smit, P.J. Souliotis, K. Speiciene, D. Sperl, J. Stärkel, P. Struck, D. Sypsa, V. Thornton, L. Tolmane, I. Tomasiewicz, K. Valantinas, J. Van Damme, P. van de Vijver, D. van der Meer, A.J. van Santen, D. Van Vlierberghe, H. Vandijck, D. Vella, S. Videčnik-Zorman, J. Vogel, W. Weis, N. Hatzakis, A. The European Union HCV Collaborators

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% red

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::eab514bb2a476338e78c377cede35de6
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3126194

Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.

Autor: Marzi, Luca¹ (AUTHOR) andrea.mega@sabes.it, Mega, Andrea¹ (AUTHOR) chiara.turri@sabes.it, Turri, Chiara¹ (AUTHOR), Gitto, Stefano² (AUTHOR) stefano.gitto@unifi.it, Ferro, Federica³ (AUTHOR) federica.ferro@sabes.it, Spizzo, Gilbert⁴ (AUTHOR) gilbert.spizzo@gmail.com

Publikováno v: International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11676. 25p.

Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era

Autor: Berden, F.A.C., Kievit, W., Baak, L.C., Bakker, C.M., Beuers, U., Boucher, C.A.B., Brouwer, J.T., Burger, D.M., Erpecum, K.J.L. van, Hoek, B. van, Hoepelman, A.I.M., Honkoop, P., Kerbert-Dreteler, M.J., Knegt, R.J. de, Koek, G.H., Nieuwkerk, C.M.J. van, Soest, H. van, Tan, A.C.I.T.L., Vrolijk, J.M., Drenth, J.P.H.

Publikováno v: Netherlands Journal of Medicine, 72(8), 388-400
Scopus-Elsevier
Netherlands Journal of Medicine, 72, 388-400
Netherlands Journal of Medicine, 72(8), 388-400. Van Zuiden Communications
Netherlands Journal of Medicine, 72, 8, pp. 388-400
Netherlands journal of medicine, 72(8), 388-400. Van Zuiden Communications BV

Item does not contain fulltext BACKGROUND: A new era for the treatment of chronic hepatitis C is about to transpire. With the introduction of the first-generation protease inhibitors the efficacy of hepatitis C treatment improved significantly. Since

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ef391b3860a30b9ed8953fe4e27e9b9a
http://hdl.handle.net/1887/117363

WFUMB Review Paper. Incidental Findings in Otherwise Healthy Subjects, How to Manage: Liver.

Autor: Șirli, Roxana^1,2 (AUTHOR) roxanasirli@gmail.com, Popescu, Alina^1,2 (AUTHOR) alinamircea.popescu@gmail.com, Jenssen, Christian^3,4 (AUTHOR) c.jenssen@khmol.de, Möller, Kathleen⁵ (AUTHOR) k.moeller@live.de, Lim, Adrian⁶ (AUTHOR) a.lim@imperial.ac.uk, Dong, Yi⁷ (AUTHOR) drdaisydong@hotmail.com, Sporea, Ioan^1,2 (AUTHOR) isporea@umft.ro, Nürnberg, Dieter^4,8 (AUTHOR) nuernbergdieter@gmx.de, Petry, Marieke⁹ (AUTHOR) marieke.petry@gmx.de, Dietrich, Christoph F.⁹ (AUTHOR) c.f.dietrich@googlemail.com

Publikováno v: Cancers. Aug2024, Vol. 16 Issue 16, p2908. 21p.

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C

Autor: Knegt, R.J. de, Bezemer, G., Gool, A.R. van, Drenth, J.P.H., Hansen, B.E., Droogleever Fortuyn, H.A., Weegink, C.J., Hengeveld, M.W., Janssen, H.L.

Publikováno v: Alimentary pharmacology & therapeutics, 34(11-12), 1306-1317. Wiley-Blackwell
Alimentary Pharmacology & Therapeutics, 34, 11-12, pp. 1306-1317
Alimentary Pharmacology & Therapeutics, 34, 1306-1317

Item does not contain fulltext Aliment Pharmacol Ther 2011; 34: 1306-1317 SUMMARY: Background Treatment of hepatitis C with peginterferon and ribavirin is associated with psychiatric side-effects, frequently necessitating dose reduction or therapy ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5f4d60f38191ec507a1bb727a277058e
https://pure.amc.nl/en/publications/randomised-clinical-trial-escitalopram-for-the-prevention-of-psychiatric-adverse-events-during-treatment-with-peginterferonalfa2a-and-ribavirin-for-chronic-hepatitis-c(67e243f4-5d41-4827-8582-7caf15d7a2c2).html